461 Shares in Eli Lilly and Company (NYSE:LLY) Purchased by OneAscent Wealth Management LLC

OneAscent Wealth Management LLC bought a new position in Eli Lilly and Company (NYSE:LLY) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 461 shares of the company’s stock, valued at approximately $359,000.

Several other hedge funds also recently bought and sold shares of LLY. Trexquant Investment LP acquired a new position in Eli Lilly and Company in the 3rd quarter worth about $3,874,000. Morningstar Investment Services LLC increased its position in Eli Lilly and Company by 112.8% in the 3rd quarter. Morningstar Investment Services LLC now owns 1,741 shares of the company’s stock worth $948,000 after purchasing an additional 923 shares during the last quarter. Ancora Advisors LLC increased its position in Eli Lilly and Company by 2.9% in the 3rd quarter. Ancora Advisors LLC now owns 6,935 shares of the company’s stock worth $3,725,000 after purchasing an additional 198 shares during the last quarter. Gotham Asset Management LLC increased its position in Eli Lilly and Company by 111.3% in the 3rd quarter. Gotham Asset Management LLC now owns 7,386 shares of the company’s stock worth $3,967,000 after purchasing an additional 3,891 shares during the last quarter. Finally, Kinloch Capital LLC increased its position in Eli Lilly and Company by 25.8% in the 3rd quarter. Kinloch Capital LLC now owns 717 shares of the company’s stock worth $385,000 after purchasing an additional 147 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 9,671 shares of the firm’s stock in a transaction that occurred on Thursday, June 20th. The stock was sold at an average price of $902.67, for a total transaction of $8,729,721.57. Following the completion of the transaction, the insider now owns 97,574,139 shares in the company, valued at approximately $88,077,248,051.13. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, CAO Donald A. Zakrowski sold 750 shares of the firm’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total transaction of $614,602.50. Following the completion of the sale, the chief accounting officer now directly owns 7,130 shares of the company’s stock, valued at approximately $5,842,821.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Lilly Endowment Inc sold 9,671 shares of the firm’s stock in a transaction on Thursday, June 20th. The shares were sold at an average price of $902.67, for a total value of $8,729,721.57. Following the sale, the insider now directly owns 97,574,139 shares of the company’s stock, valued at $88,077,248,051.13. The disclosure for this sale can be found here. Insiders sold 789,704 shares of company stock worth $672,385,964 in the last 90 days. 0.13% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Citigroup increased their price objective on Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a report on Tuesday, April 2nd. BMO Capital Markets increased their price objective on Eli Lilly and Company from $900.00 to $1,001.00 and gave the company an “outperform” rating in a report on Wednesday, May 1st. The Goldman Sachs Group increased their price objective on Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a report on Thursday, April 11th. Argus increased their price objective on Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a report on Tuesday, May 14th. Finally, JPMorgan Chase & Co. increased their price objective on Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a report on Wednesday, May 1st. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $812.72.

Eli Lilly and Company Price Performance

Shares of LLY stock opened at $905.38 on Friday. The stock has a 50 day moving average of $814.40 and a two-hundred day moving average of $739.86. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. Eli Lilly and Company has a 12 month low of $434.34 and a 12 month high of $915.54. The company has a market capitalization of $860.48 billion, a P/E ratio of 133.34, a P/E/G ratio of 1.97 and a beta of 0.36.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Monday, May 6th. The company reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. The company had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The company’s quarterly revenue was up 26.0% on a year-over-year basis. During the same quarter last year, the company earned $1.62 EPS. As a group, equities analysts expect that Eli Lilly and Company will post 13.76 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be given a dividend of $1.30 per share. The ex-dividend date is Thursday, August 15th. This represents a $5.20 annualized dividend and a dividend yield of 0.57%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.